Multiple Sclerosis

Medical cannabis was legalised in the UK in 2018 for patients with health conditions known to respond to cannabis-based treatments, if conventional or licensed medications have failed to meet their needs. Because one of these health conditions is Multiple Sclerosis, Releaf are joining MS-UK for a free Webinar on the 21st of August, to explain how these treatments can be safely incorporated into MS treatment plans.

MS is a degenerative, inflammation-based condition that attacks the brain, spinal cord, and optic nerves. In the simplest of terms, it disrupts the flow of information between the brain and the body and can lead to issues with movement, sensation, and cognition.

The medicinal cannabis landscape is shifting in the United Kingdom, and with this shift comes increased options for people suffering from multiple sclerosis. MS, unfortunately, currently has no cure. And as the symptoms are so wide-ranging, the treatment options are focused on managing the different symptoms and attempting to slow down or stop further possible damage. There truly is no one-size-fits-all approach when it comes to treating MS. Research into both THC and CBD has shown promise when it comes to the reduction of symptoms related to MS.

While cannabis is still classed as a Class B controlled drug under the Misuse of Drugs Act 1971, in November 2018, the laws surrounding medicinal cannabis shifted in the UK. After decades of lobbying by patient advocacy organisations, doctors, and scientists, medicinal cannabis was finally made available on prescription for patients suffering from certain conditions, with multiple sclerosis (MS) making it on the list.